Pfizer and BioNTech’s COVID-19 Vaccines Training Resources for All Healthcare Providers led by Pfizer Vaccines US Medical Affairs
Pfizer and BioNTech’s COVID-19 Vaccines Training ResourcesPfizer Vaccines US Medical Affairs |
Join LIVE immunization site training sessions for medical updates at the designated times listed |
Session Topics Include:
- Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) to provide a single booster dose at least 2 months after completion of primary vaccination with 3 doses of Pfizer-BioNTech COVID-19 Vaccine [monovalent] for individuals 6 months through 4 years of age (Maroon Cap)
- Use of currently authorized vaccines, including storage, handling, preparation, and administration
- Question and answer session
Date & Time |
|
|
Pfizer and BioNTech’s COVID-19 Vaccines Product Training Resources: |
A review of vaccine product information including preparation and administration, storage and handling, vaccine schedule and avoiding vaccination errors. |
|
Gray Caps, 12 years of age and older (DO NOT DILUTE): Click here |
13:20 min Video |
Orange Caps, 5 through 11 years of age (DILUTE BEFORE USE): Click here |
11:48 min Video |
Maroon Caps, 6 months through 4 years of age (DILUTE BEFORE USE): |
Update will be available soon |
Storage and Handling: Click here |
11:10 min Video |
Additional COVID-19 Vaccine Resources |
Pfizer and BioNTech’s COVID-19 Vaccines HCP site: |
|
Pfizer Medical Information: |
www.pfizermedinfo.com or 1-800-438-1985 |
PfizerPro Medical: |
Continuing medical education is NOT associated with this content
Emergency uses of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or
licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease (COVID-19) in individuals aged 6 months and older as appropriate. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of
the FD&C Act unless the declaration is terminated or authorization revoked sooner.
Before administration, please see full Prescribing Information: 12 years of age and older or appropriate EUA Fact Sheet for Vaccination Providers. For the most recent prescribing information and fact sheets, please visit www.cvdvaccine-us.com